Sensei Biotherapeutics Raises $200 Million PIPE Ahead of June 2026 Shareholder Vote

*TL;DR – Sensei Biotherapeutics closed a $200 million private‑placement of Series B Preferred shares on Feb. 20, 2026. The shares will automatically convert into 1,000 common shares each if shareholders approve the pending vote on June 10, 2026.*

Context

Sensei Biotherapeutics (ticker: SENS) completed a merger with Faeth Therapeutics in mid‑February, issuing 10,497,098 shares of Series B Non‑Voting Convertible Preferred Stock to Faeth’s owners. Simultaneously, the company launched a private‑placement (PIPE) to raise additional capital. PIPEs allow companies to sell securities directly to a limited group of investors, bypassing a public offering and often at a discount to market price.

Key Facts

- The PIPE issued 14,440,395 as‑converted Series B Preferred shares at $13.85 per share, generating $200 million in gross proceeds. - Each preferred share is structured to convert into 1,000 common shares upon shareholder approval, subject to ownership limits that prevent any holder from exceeding regulatory thresholds. - The conversion will occur automatically three business days after a favorable vote on the “Parent Stockholder Matters,” scheduled for June 10, 2026. - The financing closed on Feb. 20, 2026, three days after the merger agreement was signed on Feb. 17, 2026.

What It Means

The $200 million infusion bolsters Sensei’s balance sheet ahead of the upcoming vote, providing runway for its combined pipeline with Faeth. Converting the preferred shares into common stock will dilute existing shareholders but expands the float, potentially improving liquidity for the ticker. The conversion ratio of 1,000‑to‑1 is typical for high‑growth biotech firms that use preferred equity to lock in a fixed conversion price while preserving upside for investors.

From a market perspective, the financing size places Sensei among mid‑stage biotech companies that raise between $150 million and $250 million in PIPEs to fund late‑stage clinical programs. The $13.85 per‑share price reflects a modest premium to the pre‑announcement trading level, indicating investor confidence in the merger’s strategic fit.

The June 10 vote is the next critical milestone. Approval will trigger the conversion, increase the share count, and likely prompt a reassessment of Sensei’s market capitalization. Investors will watch the vote outcome, the post‑conversion share price movement, and any subsequent guidance on product development milestones.